MCM2 and breast cancer: Even taking confounding factors related to the limited size of the present series, the lack of follow-up information in roughly one-third of cases and the low number of pT1 cases into account and putting the findings into a very careful perspective, our data suggest Mcm2 expression to be superior to Ki67 in predicting the clinical course of Ta/T1 BC.